Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T15:17:15.338Z.
Calculation as of: 2026-10-06T15:17:15.338Z.
Quote observation: 2026-10-06T15:15:26.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5055be797218969f54b4ba6f74251721a3824cc5143f897fa443291008c6f72f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$70.95M
Price/FCF Ratio
N/A
TTM Avg
1291.26
3Y Avg
1291.26
5Y Avg
1291.26
Market Cap
$68.42M
Price/FCF Ratio
0.54
TTM Avg
0.74
3Y Avg
0.74
5Y Avg
0.74
Market Cap
$68.08M
Price/FCF Ratio
N/A
TTM Avg
17.09
3Y Avg
24.44
5Y Avg
36.17
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| iBio, Inc. (IBIO) | $71.38M | N/A | N/A | N/A | N/A |
| MindWalk Holdings Corp. (HYFT)vs › | $70.95M | N/A | 1291.26 | 1291.26 | 1291.26 |
| Gain Therapeutics, Inc. (GANX)vs › | $74.00M | N/A | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIO)vs › | $68.42M | 0.54 | 0.74 | 0.74 | 0.74 |
| Champions Oncology, Inc. (CSBR)vs › | $68.08M | N/A | 17.09 | 24.44 | 36.17 |
| Hyperfine, Inc. (HYPR)vs › | $76.11M | N/A | N/A | N/A | N/A |
| Gossamer Bio, Inc. (GOSS)vs › | $65.93M | N/A | 35.77 | 35.77 | 35.77 |
| Cingulate Inc. (CING)vs › | $65.41M | N/A | N/A | N/A | N/A |
| Outset Medical, Inc. (OM)vs › | $77.44M | N/A | N/A | N/A | N/A |
| Heron Therapeutics, Inc. (HRTX)vs › | $65.19M | N/A | 1.90 | 1.90 | 1.90 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
